2. Amyotrophic lateral sclerosis Clinical trials / Disease details

Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03293069 (ClinicalTrials.gov)	January 1, 2019	21/9/2017	Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis	Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone	Amyotrophic Lateral Sclerosis	Drug: Deferiprone;Drug: Placebo Oral Tablet	University Hospital, Lille	Ministry of Health, France	Active, not recruiting	18 Years	75 Years	All	372	Phase 2/Phase 3	France
2	EUCTR2017-003763-35-FR (EUCTR)	17/05/2018	05/03/2018	conservative iron chelation by deferiprone for amyotrophic lateral sclerosis	Conservative Iron Chelation by Deferiprone as a disease-modifying Strategy for Amyotrophic Lateral Sclerosis using a Multicentre Parallel group, placebo controlled, Randomized clinical trial - FAIR ALS II	De novo Amyotrophic Lateral Sclerosis patients;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Deferiprone DR INN or Proposed INN: DEFERIPRONE	centre hospitalier universitaire de Lille	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	France
3	NCT02164253 (ClinicalTrials.gov)	September 2013	20/5/2014	Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients	Feasibility and Safety Pilot Therapeutic Study of the Iron Chelator Deferiprone in Amyotrophic Lateral Sclerosis	ALS (Amyotrophic Lateral Sclerosis);Iron Overload	Drug: Deferiprone	University Hospital, Lille	ApoPharma	Completed	18 Years	85 Years	All	23	Phase 2	France
4	NCT02880033 (ClinicalTrials.gov)	February 2011	3/8/2016	Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes	Modulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral Sclerosis	Parkinson's Disease;Amyotrophic Lateral Sclerosis;Oxidative Stress;Iron Overload	Drug: deferiprone;Drug: placebo	University Hospital, Lille	NULL	Completed	18 Years	80 Years	All	90	N/A	France